Ioflupane 123I

Drug Profile

Ioflupane 123I

Alternative Names: DaTSCAN; DaTscan; Ioflupane (123I); Radio-labelled ioflupane; β-CIT-FP

Latest Information Update: 04 Sep 2015

Price : $50

At a glance

  • Originator GE Healthcare
  • Class Diagnostic agents; Nortropanes; Small molecules
  • Mechanism of Action Dopamine plasma membrane transport protein modulators; Single-photon emission-computed tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Dementia; Lewy body disease; Multiple system atrophy; Parkinsonian disorders; Progressive supranuclear palsy

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 27 Apr 2015 Ioflupane 123I licensed to Nihon Medi-Physics in Japan before April 2015
  • 07 May 2014 Efficacy and adverse events data from a pooled analysis of four clinical trials in Parkinsonian disorders presented at the 66th Annual Meeting of the American Academy of Neurology(AAN-2014)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top